Novavax, Inc. (NVV1.F)
EUR 5.7
(-3.99%)
EUR 5.7
(-3.99%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -566.51 Million USD | 12.13% |
| 2022 | -644.73 Million USD | 61.77% |
| 2021 | -1.68 Billion USD | -304.73% |
| 2020 | -416.71 Million USD | -245.59% |
| 2019 | -120.58 Million USD | 30.67% |
| 2018 | -173.91 Million USD | -1.29% |
| 2017 | -171.71 Million USD | 36.19% |
| 2016 | -269.11 Million USD | -71.15% |
| 2015 | -157.23 Million USD | -87.88% |
| 2014 | -83.69 Million USD | -59.61% |
| 2013 | -52.43 Million USD | -76.75% |
| 2012 | -29.66 Million USD | -37.47% |
| 2011 | -21.57 Million USD | 43.94% |
| 2010 | -38.49 Million USD | -2.97% |
| 2009 | -37.38 Million USD | -8.8% |
| 2008 | -34.36 Million USD | -13.51% |
| 2007 | -30.27 Million USD | -23.02% |
| 2006 | -24.6 Million USD | -168.31% |
| 2005 | -9.17 Million USD | 62.51% |
| 2004 | -24.46 Million USD | -52.39% |
| 2003 | -16.05 Million USD | 25.53% |
| 2002 | -21.55 Million USD | -132.93% |
| 2001 | -9.25 Million USD | 27.37% |
| 2000 | -12.74 Million USD | -177.0% |
| 1999 | -4.6 Million USD | 11.54% |
| 1998 | -5.2 Million USD | -8.33% |
| 1997 | -4.8 Million USD | 12.73% |
| 1996 | -5.5 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 160.99 Million USD | 211.16% |
| 2024 Q1 | -144.83 Million USD | 21.1% |
| 2023 Q4 | -183.56 Million USD | -46.12% |
| 2023 Q3 | -125.63 Million USD | -326.54% |
| 2023 Q2 | 55.45 Million USD | 117.73% |
| 2023 Q1 | -312.76 Million USD | -28.25% |
| 2023 FY | -566.51 Million USD | 12.13% |
| 2022 Q3 | -127.18 Million USD | 73.66% |
| 2022 FY | -644.73 Million USD | 61.77% |
| 2022 Q1 | 209.29 Million USD | 125.37% |
| 2022 Q2 | -482.96 Million USD | -330.76% |
| 2022 Q4 | -243.87 Million USD | -91.75% |
| 2021 Q1 | -208.63 Million USD | -14.1% |
| 2021 Q3 | -307.14 Million USD | 11.19% |
| 2021 Q2 | -345.82 Million USD | -65.76% |
| 2021 FY | -1.68 Billion USD | -304.73% |
| 2021 Q4 | -824.97 Million USD | -168.59% |
| 2020 FY | -416.71 Million USD | -245.59% |
| 2020 Q2 | -17.02 Million USD | 25.64% |
| 2020 Q3 | -193.94 Million USD | -1039.03% |
| 2020 Q4 | -182.85 Million USD | 5.72% |
| 2020 Q1 | -22.89 Million USD | 20.23% |
| 2019 Q2 | -36.66 Million USD | 8.84% |
| 2019 FY | -120.58 Million USD | 30.67% |
| 2019 Q4 | -28.7 Million USD | -91.53% |
| 2019 Q1 | -40.22 Million USD | 13.52% |
| 2019 Q3 | -14.98 Million USD | 59.13% |
| 2018 FY | -173.91 Million USD | -1.29% |
| 2018 Q4 | -46.51 Million USD | -11.01% |
| 2018 Q3 | -41.9 Million USD | 0.22% |
| 2018 Q2 | -41.99 Million USD | 3.49% |
| 2018 Q1 | -43.51 Million USD | 8.94% |
| 2017 Q4 | -47.78 Million USD | -14.79% |
| 2017 Q1 | -40.82 Million USD | 24.46% |
| 2017 FY | -171.71 Million USD | 36.19% |
| 2017 Q2 | -41.47 Million USD | -1.58% |
| 2017 Q3 | -41.62 Million USD | -0.38% |
| 2016 FY | -269.11 Million USD | -71.15% |
| 2016 Q3 | -63.3 Million USD | 17.24% |
| 2016 Q2 | -76.49 Million USD | -1.64% |
| 2016 Q4 | -54.04 Million USD | 14.63% |
| 2016 Q1 | -75.26 Million USD | 4.61% |
| 2015 Q2 | -20.82 Million USD | 14.36% |
| 2015 FY | -157.23 Million USD | -87.88% |
| 2015 Q4 | -78.9 Million USD | -137.66% |
| 2015 Q1 | -24.31 Million USD | 23.22% |
| 2015 Q3 | -33.19 Million USD | -59.45% |
| 2014 Q2 | -17.85 Million USD | -24.09% |
| 2014 Q3 | -19.78 Million USD | -10.86% |
| 2014 FY | -83.69 Million USD | -59.61% |
| 2014 Q4 | -31.66 Million USD | -60.01% |
| 2014 Q1 | -14.38 Million USD | -0.93% |
| 2013 Q3 | -15.27 Million USD | -18.46% |
| 2013 FY | -52.43 Million USD | -76.75% |
| 2013 Q2 | -12.89 Million USD | -28.92% |
| 2013 Q1 | -10 Million USD | -5.37% |
| 2013 Q4 | -14.25 Million USD | 6.72% |
| 2012 FY | -29.66 Million USD | -37.47% |
| 2012 Q4 | -9.49 Million USD | -38.63% |
| 2012 Q2 | -5.85 Million USD | 21.59% |
| 2012 Q1 | -7.46 Million USD | -75.32% |
| 2012 Q3 | -6.84 Million USD | -16.98% |
| 2011 Q1 | -7.43 Million USD | -5.66% |
| 2011 FY | -21.57 Million USD | 43.94% |
| 2011 Q4 | -4.25 Million USD | -7.33% |
| 2011 Q3 | -3.96 Million USD | 32.98% |
| 2011 Q2 | -5.92 Million USD | 20.31% |
| 2010 Q3 | -10.53 Million USD | -11.31% |
| 2010 Q2 | -9.46 Million USD | 17.34% |
| 2010 Q4 | -7.03 Million USD | 33.28% |
| 2010 Q1 | -11.45 Million USD | 19.08% |
| 2010 FY | -38.49 Million USD | -2.97% |
| 2009 Q2 | -7.83 Million USD | -9.71% |
| 2009 Q1 | -7.13 Million USD | 22.51% |
| 2009 FY | -37.38 Million USD | -8.8% |
| 2009 Q4 | -14.15 Million USD | -71.31% |
| 2009 Q3 | -8.26 Million USD | -5.52% |
| 2008 Q2 | -8.2 Million USD | -13.63% |
| 2008 Q1 | -7.22 Million USD | -119.05% |
| 2008 FY | -34.36 Million USD | -13.51% |
| 2008 Q3 | -9.72 Million USD | -18.55% |
| 2008 Q4 | -9.21 Million USD | 5.31% |
| 2007 Q4 | -3.29 Million USD | 64.39% |
| 2007 Q3 | -9.25 Million USD | -6.1% |
| 2007 Q2 | -8.72 Million USD | 2.97% |
| 2007 Q1 | -8.99 Million USD | -31.46% |
| 2007 FY | -30.27 Million USD | -23.02% |
| 2006 Q1 | -5.03 Million USD | -175.06% |
| 2006 Q4 | -6.84 Million USD | -20.13% |
| 2006 FY | -24.6 Million USD | -168.31% |
| 2006 Q3 | -5.69 Million USD | 19.1% |
| 2006 Q2 | -7.03 Million USD | -39.78% |
| 2005 Q4 | 6.7 Million USD | 399.87% |
| 2005 FY | -9.17 Million USD | 62.51% |
| 2005 Q3 | -2.23 Million USD | 57.19% |
| 2005 Q2 | -5.22 Million USD | 37.92% |
| 2005 Q1 | -8.41 Million USD | 15.05% |
| 2004 Q4 | -9.9 Million USD | -327.07% |
| 2004 Q1 | -4.89 Million USD | -60.0% |
| 2004 FY | -24.46 Million USD | -52.39% |
| 2004 Q3 | -2.32 Million USD | 68.39% |
| 2004 Q2 | -7.34 Million USD | -49.92% |
| 2003 Q3 | -2.96 Million USD | 36.1% |
| 2003 FY | -16.05 Million USD | 25.53% |
| 2003 Q1 | -5.4 Million USD | -10.4% |
| 2003 Q2 | -4.63 Million USD | 14.24% |
| 2003 Q4 | -3.06 Million USD | -3.38% |
| 2002 Q3 | -6.33 Million USD | -21.11% |
| 2002 Q2 | -5.23 Million USD | -2.75% |
| 2002 Q4 | -4.89 Million USD | 22.83% |
| 2002 Q1 | -5.09 Million USD | -67.13% |
| 2002 FY | -21.55 Million USD | -132.93% |
| 2001 Q2 | -1.68 Million USD | 21.88% |
| 2001 Q1 | -2.15 Million USD | 57.65% |
| 2001 Q3 | -2.37 Million USD | -41.02% |
| 2001 FY | -9.25 Million USD | 27.37% |
| 2001 Q4 | -3.04 Million USD | -28.5% |
| 2000 Q2 | -2.82 Million USD | -94.3% |
| 2000 Q3 | -3.37 Million USD | -19.42% |
| 2000 Q4 | -5.08 Million USD | -50.59% |
| 2000 FY | -12.74 Million USD | -177.0% |
| 2000 Q1 | -1.45 Million USD | -32.27% |
| 1999 Q2 | -800 Thousand USD | 11.11% |
| 1999 Q4 | -1.1 Million USD | 38.89% |
| 1999 Q3 | -1.8 Million USD | -125.0% |
| 1999 Q1 | -900 Thousand USD | 47.06% |
| 1999 FY | -4.6 Million USD | 11.54% |
| 1998 Q2 | -1.3 Million USD | -44.44% |
| 1998 Q3 | -1.3 Million USD | 0.0% |
| 1998 Q4 | -1.7 Million USD | -30.77% |
| 1998 FY | -5.2 Million USD | -8.33% |
| 1998 Q1 | -900 Thousand USD | 18.18% |
| 1997 Q2 | -1.3 Million USD | -18.18% |
| 1997 Q3 | -1.2 Million USD | 7.69% |
| 1997 FY | -4.8 Million USD | 12.73% |
| 1997 Q4 | -1.1 Million USD | 8.33% |
| 1997 Q1 | -1.1 Million USD | 38.89% |
| 1996 Q3 | -1 Million USD | 23.08% |
| 1996 Q1 | -1.1 Million USD | 0.0% |
| 1996 Q4 | -1.8 Million USD | -80.0% |
| 1996 Q2 | -1.3 Million USD | -18.18% |
| 1996 FY | -5.5 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| BioNTech SE | 690.4 Million EUR | 182.055% |
| CureVac N.V. | -274.2 Million EUR | -106.6% |
| Biotest Aktiengesellschaft | 143.5 Million EUR | 494.781% |
| Biotest Aktiengesellschaft | 143.5 Million EUR | 494.781% |
| BRAIN Biotech AG | -6.71 Million EUR | -8336.5% |
| Formycon AG | -369 Thousand EUR | -153426.016% |
| Heidelberg Pharma AG | -21.2 Million EUR | -2570.987% |
| Medigene AG | -16.14 Million EUR | -3408.025% |